Is the price fair?
What ANIP's price assumes
ANI Pharmaceuticals, Inc. trades at 18.9× earnings against 24.4× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
18.9
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.4 · cheaper than the typical name in its group
- Price / sales
- 1.79
Price / sales · as of 2026-Q1
- Free cash flow yield
- 11%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- −4.4%
Growth the price implies · The price pays for −4.4% free cash flow growth a year for a decade; revenue has grown +37% a year over the last three.
Details›
- Price / book2026-Q1
- 2.95
- EV / EBIT2026-Q1
- 13.2
- EV / sales2026-Q1
- 1.77
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.4
- Free cash flow, trailing twelve months
- $191M
- Market capitalisation
- $1.81B
- 3-year revenue growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #10 of 28 by Smart Score